Metabolomics-based profiles predictive of low bone mass in menopausal women.
Metabolomics-based profiles predictive of low bone mass in menopausal women.
复制标题
DOI：
10.1016/j.bonr.2018.06.004
复制
发表时间：
2018-12
期刊：
影响因子：
2.5
通讯作者：
Matsumoto M
中科院分区：
文献类型：
--
作者：
Miyamoto T;Hirayama A;Sato Y;Koboyashi T;Katsuyama E;Kanagawa H;Fujie A;Morita M;Watanabe R;Tando T;Miyamoto K;Tsuji T;Funayama A;Soga T;Tomita M;Nakamura M;Matsumoto M
骨质疏松症是一种骨骼疾病，其特征是骨强度受损和骨折风险增加。低骨量和/或预先存在的骨脆性骨折可作为决定何时开始骨质疏松症药物治疗的诊断标准。虽然骨质疏松症是一种代谢紊乱，但预测骨量减少的代谢标志物尚不清楚。在这里，我们使用综合代谢组学分析显示了绝经前正常骨矿物质密度（BMD）（正常雌激素和正常BMD; NN）、绝经后正常BMD（低雌激素和正常BMD; LN）或绝经后低BMD（低雌激素和低BMD; LL）女性的血清代谢组学特征。为此，我们招募了健康志愿者和骨质疏松症患者女性受试者，对她们进行了问卷调查，测量了她们的骨密度，然后对上述三组的血清进行了全面的代谢组学分析。我们鉴定了NN/LN和NN/LL组之间水平显著不同的24种代谢物，以及NN/LN和LN/LL或LN/LL和NN/LN组之间水平显著不同的18或10种代谢物。我们的数据显示，代谢组学变化是预测雌激素缺乏和/或骨质流失的有用标志物。在雌二醇正常或低、骨量正常或低的妇女中进行综合代谢组学分析。52种代谢产物被鉴定为雌激素缺乏和/或低骨量的生物标志物。代谢组学分析可以预测绝经后妇女雌激素缺乏和/或低骨密度。
Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss. Comprehensive metabolomic analysis was undertaken in women with normal or low estradiol and normal or low bone mass. 52 metabolites were identified as biomarkers of estrogen deficiency and/or low bone mass. Metabolomic profiling could predict estrogen-deficiency and/or low bone mineral density in postmenopausal women.